Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 2/20 | 0.38 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.38 |
| ▸ | ITGAV | P06756 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.38 |
| ▸ | ITGAL | P20701 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 14/20 | 0.34 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL864422 | 0.90 | — | — | |
| SCHEMBL1491235 | 0.90 | — | — | |
| SCHEMBL864423 | 0.90 | — | — | |
| Hydrochloric Acid SCHEMBL482332 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL22659576 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL30098013 | 0.88 | KCNA5 (0.34) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| Hydrochloric Acid SCHEMBL20540318 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL23250525 | 0.86 | — | — | |
| SCHEMBL16628845 | 0.80 | GABRP (0.35) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL21673085 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4234030-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12269812-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| EP-4234030-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3820572-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2023-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12269812-B2 | PD-1/PD-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | ITGB1 1781/4885ITGA5 3353/4885ITGB3 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.